New combo therapy aims to tackle resistant lymphomas
Disease control
Recruiting now
This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtype…
Phase: PHASE2 • Sponsor: Seda S. Tolu • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC